Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | DNM2 | P50570 | 1/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786146 | 0.85 | ADORA2A (0.46) | ADORA2AADORA1ADORA3MAOAMAOB | |
| SCHEMBL20078226 | 0.82 | MAOA (0.48) | ADORA2AADORA1ADORA3MAOAMAOB | |
| SCHEMBL23218553 | 0.81 | LOXL2 (0.41) | ADORA2AADORA1ADORA3MAOAMAOB | |
| SCHEMBL2304012 | 0.81 | CA12 (0.45) | ADORA2AADORA1ADORA3CA12CA1 | |
| SCHEMBL9524775 | 0.77 | ALDH1A1 (0.49) | ADORA1KMT2AALDH1A1MCL1HDAC6 | |
| SCHEMBL73352 | 0.77 | LMNA (0.56) | ADORA2AADORA1ADORA3CA12CA1 | |
| SCHEMBL18397734 | 0.77 | LOXL2 (0.72) | MAOAMAOBLOXL2MEN1KMT2A | |
| SCHEMBL29891715 | 0.75 | LCK (0.48) | ADORA2AADORA1LCKKMT2AALDH1A1 | |
| SCHEMBL28633012 | 0.75 | LCK (0.48) | ADORA2AADORA1LCKKMT2AALDH1A1 | |
| SCHEMBL11340926 | 0.74 | CYP2D6 (0.38) | CA12CA1CA2CA9LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761410-B | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022213932-A1 | PYRROLOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF | 广州必贝特医药股份有限公司 | 2022-10-13 | — | — | WO | disclosed |
| CN-114761410-A | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-1105370-B9 | NOVEL ARYL SULPHONAMIDES AND ANALOGUES | BAYER HEALTHCARE AG (DE) | 2005-01-12 | — | — | EP | disclosed |
| US-6727279-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-27 | — | — | US | disclosed |
| EP-1105370-B1 | NOVEL ARYL SULPHONAMIDES AND ANALOGUES | BAYER HEALTHCARE AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030073727-A1 | Novel arylsulphonamides and analogues | MITTENDORF JOACHIM (DE) | 2003-04-17 | — | — | US | disclosed |
| US-6469054-B1 | PROPHYLAXIS AND TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR FOR THE TREATMENT OF CEREBRAL APOPLEXY, CRANIOCEREBRAL TRAUMA, PAIN AND SPASTICITY | BAYER AKTIENGESELLSHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| EP-1105370-A1 | NOVEL ARYL SULPHONAMIDES AND ANALOGUES | Bayer Aktiengesellschaft (DE) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000010967-A1 | NOVEL ARYL SULPHONAMIDES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073727-A1 | Novel arylsulphonamides and analogues | PRSS12, OPRL1, CTSH | ADORA2A 354/4885ADORA1 539/4885ADORA3 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.